Veterinary Intravenous Solutions Market: A Surge in Demand

The global veterinary intravenous (IV) solutions market was valued at USD 1.45 billion in 2024 and is expected to reach USD 2.07 billion by 2030, expanding at a CAGR of 6.21% from 2025 to 2030. The increasing burden of chronic diseases among animals is a key factor supporting market growth. For example, an article published by International Cat Care in February 2025 reported that chronic kidney disease (CKD) can develop in cats of all ages but is most commonly diagnosed in middle-aged and senior cats, particularly those over seven years old. It is estimated that around 20% to 50% of cats aged 15 years and above show some degree of CKD.

The rising adoption of pet insurance across the globe is also significantly contributing to the demand for veterinary IV solutions. As veterinary treatment costs continue to increase, pet insurance enables owners to better manage expenses and pursue advanced treatment options, particularly in emergency and critical care settings where IV therapy is vital. Intravenous therapy plays a crucial role in managing conditions such as dehydration, infections, post-operative recovery, renal disorders, and toxin exposure—many of which are covered under pet insurance plans. The availability of reimbursement encourages pet owners to opt for timely and intensive care rather than postponing treatment due to financial constraints.

According to the North American Pet Health Insurance Association (NAPHIA), approximately 7.03 million pets in North America were insured by the end of 2024, reflecting a 12.2% increase from 6.25 million insured pets in 2023. In addition, a 2024 article by PetMD noted that horse insurance premiums typically range from USD 300 to USD 3,000, with standard plans covering diagnostics, treatments, and surgeries, including those for chronic conditions. As pet owners increasingly focus on the long-term health of companion animals such as horses and dogs, these factors are expected to further stimulate growth in the veterinary IV solutions market.

Order a free sample PDF of the Veterinary Intravenous Solutions Market Intelligence Study, published by Grand View Research.

Key Market Trends & Insights

• Regional Insights: North America led the global market in 2024, accounting for over 38.09% of total revenue. This dominance is primarily driven by the high prevalence of both chronic and acute diseases among companion animals. Conditions including CKD, gastrointestinal disorders, trauma, and infectious diseases often require supportive fluid therapy, making IV solutions a critical component of veterinary care. For instance, CKD affects up to 80% of cats over 15 years of age in the U.S., and IV fluids are essential for maintaining hydration and removing toxins.
• By Product: The isotonic crystalloids segment held the largest market share in 2024, accounting for more than 42.00% of revenue. These solutions are widely used in veterinary medicine due to their ability to restore fluid and electrolyte balance without causing significant shifts between body compartments. With osmolality comparable to blood plasma, isotonic crystalloids are effective in treating dehydration, shock, and acid–base disturbances. They can be administered via multiple routes, including intravenous, intraosseous, subcutaneous, and intraperitoneal. Commonly used isotonic solutions include Lactated Ringer’s, 0.9% normal saline, Ringer’s solution, acetated Ringer’s, 2.5% dextrose in 0.45% saline, and Plasma-Lyte A.
• By Animal Type: The companion animal segment dominated the market in 2024, representing over 58.0% of total revenue. High rates of pet ownership, particularly of dogs and cats, drive substantial demand for veterinary IV therapy for routine treatments, surgeries, and emergency care. According to the American Pet Products Association (APPA), the U.S. had more than 65.1 million dogs in 2024, making it the country with the largest pet population. Additionally, data from a 2021 Rakuten Insights survey indicated that more than 32% of households in Asia own a dog, further supporting global demand growth.
• By Indication: The diabetic ketoacidosis (DKA) segment accounted for over 28.0% of market revenue in 2024. The occurrence of DKA is closely associated with the prevalence of diabetes mellitus in animals, particularly dogs and cats. As the incidence of diabetes in companion animals continues to rise, the number of DKA cases is also increasing. IV fluid therapy is a fundamental component in the management of DKA, as it helps correct dehydration, stabilize electrolyte imbalances, and support glucose and insulin administration in animals experiencing this life-threatening condition.
• By End Use: The “others” segment is projected to register the fastest CAGR during the forecast period. This growth is attributed to the increasing adoption of veterinary home care services, where animals receive treatment in their own homes. In these settings, veterinary professionals administer IV solutions as part of in-home medical care. Home-based treatment offers greater convenience, reduces stress for animals, and enhances comfort for both pets and owners, making it an increasingly preferred option.

Market Size & Forecast

• 2024 Market Size: USD 1.45 Billion
• 2030 Projected Market Size: USD 2.07 Billion
• CAGR (2025-2030): 6.21%
• North America: Largest market in 2024

Key Companies & Market Share Insights

The veterinary IV solutions market is highly competitive, with several established players driving innovation and expansion. Technological advancements remain a key factor influencing competition. To strengthen their market positions and broaden product offerings, leading companies are actively pursuing strategies such as mergers and acquisitions, strategic collaborations, and the introduction of new and advanced IV solution products.

Key Players

• Merck & Co., Inc (Animal Health
• Dechra
• Animalcare Limited
• B. Braun Vet Care (B Braun SE)
• Elanco Animal Health Incorporated (Animal Health
• Zoetis Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global veterinary intravenous solutions market is poised for steady growth through 2030, driven by the rising prevalence of chronic and acute animal diseases, increasing pet ownership, and expanding adoption of pet insurance. The growing emphasis on advanced veterinary care, combined with the expanding role of companion animals and the emergence of home-based veterinary services, continues to fuel demand for IV therapies. With North America maintaining its leadership position and isotonic crystalloids remaining the dominant product segment, the market is expected to experience sustained expansion supported by innovation, strategic partnerships, and improved access to quality animal healthcare.